Drug updated on 11/28/2023

Dosage FormCapsule (oral; 150 mg)
Drug ClassIsocitrate dehydrogenase-1 inhibitors
Ongoing and Completed StudiesClinicalTrials.gov


  • Indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.

Product Monograph / Prescribing Information

Document TitleYearSource
Rezlidhia (olutasidenib) Prescribing Information.2022Rigel Pharmaceuticals, Inc. South San Francisco, CA

Randomized Controlled Trials